Ocera doses first patient in Phase IIa trial of OCR-002 to treat cirrhosis

Ocera Therapeutics has started dosing patients in the Phase IIa part of its Phase I/IIa clinical trial of oral OCR-002 (ornithine phenylacetate) for the treatment of cirrhosis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news